TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
Hematological Oncology · 2025-07 · 43 (4)
DOI: 10.1002/hon.70106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 03.06.2025. Verfasst von Antonella Bruzzese und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health-Ricerca Corrente Program.
Abstract (Originalsprache)
TP53 ‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This review evaluates the efficacy of various treatment approaches, including intensive chemotherapy (IC), hypomethylating agents (HMAs), venetoclax‐based regimens, and immune checkpoint inhibitors. Additionally, we discuss emerging strategies such as p53 reactivation, multi‐targeted inhibition, and novel immunotherapies, including bispecific T‐cell engagers (BiTEs) and CAR‐T cell therapy. Current treatment options provide limited benefits in TP53 ‐mutated AML, with complete remission rates ranging from 13% to 46% and median overall survival of only 6.1–6.5 months. Allogeneic stem cell transplantation (allo‐SCT) offers minimal survival advantage due to high relapse rates. Despite promising preclinical data, checkpoint inhibitors and TIM‐3 blockade have failed to demonstrate significant clinical efficacy, likely due to the immunosuppressive tumor microenvironment. Novel approaches, such as APR‐246 (eprenetapopt) and MCL‐1/CHK1 inhibitors, are under investigation, but their therapeutic impact remains uncertain. The failure of single‐agent therapies underscores the need for combination strategies targeting multiple resistance mechanisms. Future research should focus on integrating targeted inhibitors with immunotherapy and bone marrow microenvironment modifiers. While TP53 ‐mutated AML remains a formidable challenge, ongoing advances in precision medicine and immunotherapy hold the potential to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- Laboratory of Translational Reserach Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.
- Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Francesco Mendicino
Förderung
- Italian Ministry of Health-Ricerca Corrente Program
Zitieren
APA
Bruzzese, A., Vigna, E., Martino, E. A., Labanca, C., Caridà, G., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., & Gentile, M. (2025). TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions. Hematological Oncology, 43(4). https://doi.org/10.1002/hon.70106
Vancouver
Bruzzese A, Vigna E, Martino EA, Labanca C, Caridà G, Mendicino F, et al. TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions. Hematological Oncology. 2025;43(4). doi:10.1002/hon.70106
BibTeX
@article{Bruzzese2025,
author = {Bruzzese, Antonella and Vigna, Ernesto and Martino, Enrica Antonia and Labanca, Caterina and Caridà, Giulio and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Puccio, Noemi and Neri, Antonino and Morabito, Fortunato and Gentile, Massimo},
title = {TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {4},
doi = {10.1002/hon.70106}
}
EUVIMED